In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Editas Medicine (EDIT – Research Report), ...
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...
Nobel Prize winner and CRISPR DNA-editing pioneer Jennifer A. Doudna, PhD, spoke September 19 at Fred Hutch Cancer Center in Seattle. Her lecture kicked off the President’s Seminar series, presented ...
Editas Medicine ( (EDIT)) has issued an update. Editas Medicine, Inc. struck a deal on October 3, 2024, with a subsidiary of DRI Healthcare Trust, selling future license fees and payments from ...
Ben Affleck is rocking a new look amid his ongoing divorce from Jennifer Lopez. In photos obtained by Page Six and taken on Thursday, October 3, Affleck, 52, was spotted in Santa Monica ...
Editas sells future CRISPR licensing fees from Vertex: DRI Healthcare Trust is paying $57 million upfront to the gene editing company … ...
On Friday, Leerink Partners maintained a Market Perform rating on Editas Medicine (NASDAQ:EDIT), with a consistent price target of $8.00. This decision follows Editas Medicine's recent announcement of ...
Jennifer Gledhill, 41 of Cottonwood Heights, was arrested Wednesday and is jailed in Salt Lake County without bond, according to court records. The body of Matthew Johnson, 51, had not been found ...
Now, Editas has sold on some of those same rights ... Ph.D. Alongside fellow Nobel Prize laureate Jennifer Doudna, Ph.D., Charpentier created a type of genetic scissors that can be used to cut ...
Editas will also give up part of a potential ... Prize in Chemistry that was awarded to Emmanuelle Charpentier and Jennifer Doudna. Charpentier is the founder of CRISPR Therapeutics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback